Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Melanoma

MSLT-1—SNB is a biomarker, not a therapeutic intervention

Nature Reviews Clinical Oncology volume 11, pages 248–249 (2014)Cite this article

Subjects

The final analysis of the MSLT-1 trial confirms that sentinel lymph node biopsy (SNLB) does not improve survival in patients with melanoma >1 mm thickness. Subgroup analyses remain inconclusive. SNLB provides prognostic information for adjuvant therapy decisions, as recent data indicate that adjuvant therapies are effective in patients with positive sentinel nodes with an ulcerated primary.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Eggermont, A. M., Spatz, A. & Robert, C. Cutenous melanoma. Lancet 383, 816–827 (2014).

    Article  CAS  Google Scholar 

  2. Balch, C. M. et al. Final version of 2009 AJCC melanoma staging and classification. J. Clin. Oncol. 27, 6199–6206 (2009).

    Article  Google Scholar 

  3. van der Ploeg, A. P. et al. Prognosis in patients with sentinel node-positive melanoma is accurately defined by the combined Rotterdam tumor load and Dewar topography criteria. J. Clin. Oncol. 29, 2206–2214 (2011).

    Article  Google Scholar 

  4. Eggermont, A. M. et al. Ulceration and stage are predictive of interferon efficacy in melanoma: Results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. Eur. J. Cancer 48, 218–225 (2012).

    Article  CAS  Google Scholar 

  5. Morton, D. L. et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N. Engl. J. Med. 370, 599–609 (2014).

    Article  CAS  Google Scholar 

  6. Thomas, J. M. Prognostic false-positivity of the sentinel node in melanoma. Nat. Clin. Pract. Oncol. 5, 18–23 (2008).

    Article  Google Scholar 

  7. Altstein, L. & Li, G. Latent subgroup analysis of a randomized clinical trial through a semiparametric accelerated failure time mixture model. Biometrics 69, 52–61 (2013).

    Article  CAS  Google Scholar 

  8. Eggermont, A. M. M. et al. Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma. J. Clin. Oncol. 30, 3810–3818 (2012).

    Article  CAS  Google Scholar 

  9. Voit, C. A. et al. Rotterdam Criteria for sentinel node (SN) tumor burden and the accuracy of ultrasound (US)-guided fine-needle aspiration cytology (FNAC): can US-guided FNAC replace SN staging in patients with melanoma? J. Clin. Oncol. 27, 4994–5000 (2009).

    Article  Google Scholar 

  10. Voit, C. et al. Ultrasound morphology criteria predict metastatic disease of the sentinel nodes in patients with melanoma. J. Clin. Oncol. 28, 847–852 (2010).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgical Oncology, Netherlands Cancer Institute, Antoni van Leeuwenhoek, Plesmanlaan 121, Amsterdam, 1066, CX, The Netherlands

    Alexander C. J. van Akkooi

  2. Cancer Institute, Gustave Roussy Cancer Campus, Grand Paris, 114 rue Édouard Vaillant, Villejuif, 94805, France

    Alexander M. M. Eggermont

Authors
  1. Alexander C. J. van Akkooi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alexander M. M. Eggermont
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alexander C. J. van Akkooi.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

van Akkooi, A., Eggermont, A. MSLT-1—SNB is a biomarker, not a therapeutic intervention. Nat Rev Clin Oncol 11, 248–249 (2014). https://doi.org/10.1038/nrclinonc.2014.64

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrclinonc.2014.64

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing